Skip to search boxSkip to navigationSkip to main content

Ifosfamide-induced nephrogenic diabetes insipidus and Fanconi syndrome in a patient with femur osteosarcoma

  • ,
  • Guillermo Ramos-Torres
    ,
  • Juan Quiroz-Aldave
    ,
  • María del Carmen Durand-Vásquez
    ,
  • Sofía Ildefonso-Najarro
    ,
  • Elena de Jesús Alvarado-León
  • ,
  • Hospital Guillermo Almenara Irigoyen
    ,
  • Hospital de Apoyo Chepén
    ,
  • Universidad Nacional de Trujillo
    ,
  • Hospital Belén de Trujillo
    ,
  • Hospital Nacional Edgardo Rebagliati Martins, EsSalud
Research Output:
Contribution to journal
Article
Peer-review

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 743-747 (5 pages)

Journal (Volume, Issue Number)

Caspian Journal of Internal Medicine (Volume 15, Issue 4)

Publication milestones

  • Published - 09/2024

Publication status

Published - 09/2024

ISSN

2008-6164

Publication IDs

  • Scopus: 85204226991

Abstract

Background: Ifosfamide-induced Fanconi syndrome is a relatively infrequent complication that generally occurs in young patients with a high cumulative dose of ifosfamide; and is commonly characterized by glycosuria, proteinuria, electrolyte abnormalities, and a normal anion gap metabolic acidosis. Case Presentation: In this study, we present the case of a 16-year-old male patient with of osteosarcoma of the right femur with pulmonary metastasis, who received ifosfamide as part of chemotherapy 1 year and 2 months ago and required hospitalization for cellulitis. During inpatient management, he presented with hypokalemia, hypophosphatemia, polyuria, glycosuria, and proteinuria, by which he was diagnosed with Fanconi syndrome and nephrogenic diabetes insipidus, induced by ifosfamide. Management was focused on the control of the internal environment and use of potassium supplements and potassium-sparing diuretics. Conclusion: Patients receiving ifosfamide should be periodically monitored for kidney function and internal environment to detect any potential complications. It is thus important to carefully observe the cumulative dose of ifosfamide to prevent its associated nephrotoxicity, since its appearance can impoverish the prognosis in patients with neoplasms. Therefore, physicians should always be aware about the possibility of nephrotoxicity development.

Publication metrics

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well